Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial

May 31, 2026

,

Atkins, M. et al.

ASCO

Phase II Trial

Melanoma

View Publication

Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200

Our Science

Pipeline

Publications

Clinical Trials

Immunotherapy

About BOT + BAL

Company

Our History

Our Team

Careers

Partners

Access

Patient Access

Contact Medical Affairs

Resources

Press Releases

In the News

Patient Resources

FAQs

Investors

Investor Overview

Events

Financial Information

Opt-out preferences Cookie Policy Terms and Conditions of Use Privacy Policy Community Guidelines Access to Investigational Medicines Policy Report Adverse Event Investor Portal

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Publishing the Frontiers of Immuno-Oncology

Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial

Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.

Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials .

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Publishing the Frontiers of Immuno-Oncology

Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial

Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.

Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4) for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials .

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.

Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials .